Early and Late Efficacy of Vorapaxar Among the Subgroup of Patients with a Prior MI Cohort.
Reproduced with permission from The Lancet; Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: A prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Scirica BM et al. 2012;doi:10.1016/S0140–6736(12)61269–0.
CV=cardiovascular; GUSTO=Global Use of Strategies to Open Occluded coronary arteries; ICH-intracranial hemorrhage; KM=Kaplan-Meier; TIMI=Thrombolysis in Myocardial Infarction; UCR-urgent coronary revascularization.Reproduced with permission from BM Scirica, MD.